Results 11 to 20 of about 47,826 (189)

Overall Survival With Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2‐Positive Metastatic Breast Cancer: A Single‐Center Pooled Analysis

Thoracic Cancer
Background Phase II and III trials have demonstrated progression‐free survival (PFS) benefits of pyrotinib plus capecitabine over lapatinib plus capecitabine in HER2‐positive metastatic breast cancer (MBC).
Jialin Lin, Qiao Li, Pin Zhang, Ying Fan, Ruigang Cai, Yang Luo, Bo Lan, Shanshan Chen, Jiani Wang, Hongnan Mo, Fei Ma, Jiayu Wang, Binghe Xu   +12 more
doaj   +2 more sources

Visfatin and Resveratrol Differentially Regulate the Expression of Thymidylate Synthase to Control the Sensitivity of Human Colorectal Cancer Cells to Capecitabine Cytotoxicity

Life, 2021
Colorectal cancer (CRC) is a highly lethal malignant cancer. Capecitabine, a 5-fluororacil (5-FU) derivate, is its first-line drug, but the resistance of CRC to capecitabine is still the most challenging factor for curing patients.
Kuen-Lin Wu, Ko-Chao Lee, Chia-Kuang Yen, Cheng-Nan Chen, Shun-Fu Chang, Wen-Shih Huang   +5 more
doaj   +1 more source

Clinical pharmacokinetics of capecitabine and its metabolites in colorectal cancer patients

Saudi Pharmaceutical Journal, 2022
Background: Capecitabine is one of the fluoropyrimidine anticancer agents which is extensively used in the management of colorectal cancer. We have noticed a discrepancy between the doses we are using in our patients and the recommended dosing regimen ...
Saeed Alqahtani, Rawan Alzaidi, Abdullah Alsultan, Abdulaziz Asiri, Yousif Asiri, Khalid Alsaleh   +5 more
doaj   +1 more source

Capecitabine-Associated Terminal Ileitis

Case Reports in Oncology, 2018
Capecitabine is an oral fluoropyrimidine used as adjuvant and palliative chemotherapy in patients with colorectal cancer. Diarrhea is a well-known side effect of capecitabine and 5-fluorouracil agents.
Irene E.G. van Hellemond, Annemarie M. Thijs, Geert-Jan Creemers   +2 more
doaj   +1 more source

Effect of capecitabine on breast cancer patients with different estrogen receptor status

Bangladesh Journal of Pharmacology, 2020
This meta-analysis is to compare the efficacy of capecitabine versus non-capecitabine chemotherapy on breast cancer patients with different estrogen receptor (ER) status.
Gang Xu, Xin Lv, Ke Lu, Ming Hai Shen, Qing Hua Zhang, Wan Neng Pan   +5 more
doaj   +1 more source

Capecitabine

The Oncologist, 2007
Learning ObjectivesAfter completing this course, the reader will be able to: Identify the main toxicity profile associated with capecitabine therapy.Identify the main clinical indications for capecitabine therapy.Identify the populations at risk for severe toxicity from capecitabine therapy.CME Access and take the CME test online and receive 1 AMA PRA ...
openaire   +4 more sources

Capecitabine versus 5-fluorouracil in colorectal cancer: where are we now?

Oncology Reviews, 2011
Fluorouracil (5-FU) remains the most widely used agent for colorectal cancer. Capecitabine is a rationally designed 5-FU pro-drug developed to mimic the continuous infusion of 5-FU while avoiding complications and inconvenience of intravenous ...
Lakshmi Chintala, Susmitha Vaka, Joaquina Baranda, Stephen K. Williamson   +3 more
doaj   +1 more source

Capecitabine in Combination with Standard (Neo)Adjuvant Regimens in Early Breast Cancer: Survival Outcome from a Meta-Analysis of Randomized Controlled Trials. [PDF]

PLoS ONE, 2016
Capecitabine has been investigated in early breast cancer in several studies, but it was undefined that whether it could improve survival. To investigate whether the addition of capecitabine affected survival in patients with early breast cancer, a meta ...
Ze-Chun Zhang, Qi-Ni Xu, Sui-Ling Lin, Xu-Yuan Li   +3 more
doaj   +1 more source

Capecitabine efficacy after cycline-dependent-kinase 4/6 inhibitor plus endocrine therapy in metastatic hormone receptor-positive breast cancer

Cancer Treatment and Research Communications, 2023
Background: The combination of endocrine treatment with cycline-dependent-kinase 4/6 inhibitor is the new standard of treatment in hormone receptor-positive HER2 negative metastatic breast cancer.
L. Bender, C. Pflumio, P. Trensz, L. Pierard, M. Kalish, C. Fischbach, T. Petit   +6 more
doaj   +1 more source

Comparison of toxicity and effectiveness between fixed-dose and body surface area-based dose capecitabine

Therapeutic Advances in Medical Oncology, 2019
Background: Capecitabine is generally dosed based on body surface area (BSA). This dosing strategy has several limitations; however, evidence for alternative strategies is lacking.
Femke M. de Man, G.D. Marijn Veerman, Esther Oomen-de Hoop, Maarten J. Deenen, Didier Meulendijks, Caroline M.P.W. Mandigers, Marcel Soesan, Jan H.M. Schellens, Esther van Meerten, Teun van Gelder, Ron H.J. Mathijssen   +10 more
doaj   +1 more source